The first results from the TERAVOLT registry of patients with thoracic cancer who acquire COVID-19 have been reported at the 2020 AACR Virtual Annual Meeting I.

Data presented at the 2020 AACR Virtual Annual Meeting I add to the growing body of evidence to suggest that people with cancer have more severe outcomes when infected with SARS-CoV-2 than those without cancer.

The selective EGFR–tyrosine kinase inhibitor poziotinib has clinical activity in previously treated non-small-cell lung cancer patients harboring EGFR exon 20 insertions, suggest phase 2 study data presented at the 2020 AACR Virtual Annual Meeting I.

Primary breast cancer patients with rare pre-existing ESR1 mutations are significantly more likely to experience endocrine therapy failure in the adjuvant setting than other individuals, suggests research presented at the 2020 AACR Virtual Annual Meeting I.

Owonikoko continued: “Currently available data would suggest that antiangiogenic, immune checkpoint, and anti-EGFR or anti-RAS agents would be suitable partners for enhanced efficacy.” medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group 2020 AACR Virtual Annual Meeting I; 27–28 April

Presenting the data at the 2020 AACR Virtual Annual Meeting I, Ben Creelan (H Lee Moffitt Cancer Center, Tampa, Florida, USA) explained that TIL adoptive cell therapy has previously been used in the metastatic melanoma setting with durable complete responses in 10–15% of patients.

Speaking at the 2020 AACR Virtual Annual Meeting I, Hong reported that 79% of the 159 patients with a NTRK fusion mutation achieved an objective response to larotrectinib and 12% had stable disease.

In conclusion, Sweeney said: “Biomarker studies are ongoing and may provide further insights into these findings.” medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group 2020 AACR Virtual Annual Meeting I; 27–28 April

This difference was seen particularly in clinical trials but also in a real-world setting, emphasized Qi Liu (US Food and Drug Administration, Silver Spring, Maryland) who presented the findings at the 2020 AACR Virtual Annual Meeting I.

But the latest findings for the secondary endpoint of OS show no significant difference between the talazoparib and chemotherapy treatment arms, at a median duration of 19.3 and 19.5 months, respectively, reported Jennifer Litton (The University of Texas MD Anderson Cancer Center, Houston, USA) at the 2020 AACR Virtual Annual Meeting I.

AEs of grade 3 or 4 occurred in 58.0% of participants given the triplet regimen and 41.0% of those given chemotherapy alone, and the rates of grade 3 immune-related AEs were 19.0% and 1.6%, respectively. medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group 2020 AACR Virtual Annual Meeting I; 27–28 April

Therefore, “precise estimates of efficacy [of the combination] are confounded by a high proportion of never smokers” in the trial, and “the clinical efficacy in smokers needs to be further defined,” concluded Skoulidis. medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group 2020 AACR Virtual Annual Meeting I; 27–28 April

The findings were reported at the 2020 AACR Virtual Annual Meeting I by Steven O’Day, from the John Wayne Cancer Institute in Santa Monica, California, USA.